Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update [Yahoo! Finance]
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Company Research
Source: Yahoo! Finance
Extensive preclinical data on SON-1210 published in Frontiers in Immunology Received approval and executed agreement to sell New Jersey state net operating losses (NOLs) for expected net proceeds of $4.3 million Enrollment of the Phase 1b portion of the SON-080 trial in chemotherapy-induced peripheral neuropathy (CIPN) has completed PRINCETON, NJ / ACCESSWIRE / February 14, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapeutic drugs for cancer, announced today its financial results for the three months ended December 31, 2023 and provided a business update. "This last quarter set the stage for an exciting year across Sonnet's pipeline, highlighted by the progress of the combination study of SON-1010 and atezolizumab in platinum-resistant ovarian cancer (PROC), where we continue to expect safety data during the first half of 2024." commented Pankaj Mohan, Ph.D., F
Show less
Read more
Impact Snapshot
Event Time:
SONN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SONN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SONN alerts
High impacting Sonnet BioTherapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
SONN
News
- Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference [Yahoo! Finance]Yahoo! Finance
- Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual MeetingAccesswire
- Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective [Yahoo! Finance]Yahoo! Finance
- Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective Accesswire
SONN
Analyst Actions
- 2/15/24 - Chardan Capital
SONN
Sec Filings
- 5/3/24 - Form S-1
- 5/3/24 - Form 8-K
- 3/11/24 - Form 8-K
- SONN's page on the SEC website